文献速递复苏、休克与脓毒症

趋化因子(C-C基序)受体2拮抗剂INCB3284减少液体需求并防止失血性休克复苏期间的血流动力学失代偿

The Chemokine (C-C Motif) Receptor 2 Antagonist INCB3284 Reduces Fluid Requirements and Protects From Hemodynamic Decompensation During Resuscitation From Hemorrhagic Shock.
PubMed 文献 · Crit Care Explor · 2022-05-18
一句话结论大鼠失血性休克模型中,CCR2拮抗剂INCB3284使液体需求减少62%±6%、死亡率从50%降至零,并防止血流动力学失代偿。

该研究为随机前瞻性治疗研究,在大学实验室的雄性Sprague-Dawley大鼠中开展。健康麻醉大鼠给予递增剂量INCB3284或溶媒;失血30分钟后给予CCR2拮抗剂INCB3284(1.1和5.5 μmol/kg)、CCR5拮抗剂Maraviroc(对照,5.5 μmol/kg)或溶媒,随后液体复苏维持血压至t=90分钟;另有5 μmol/kg INCB3284或溶媒组复苏至t=300分钟。INCB3284剂量依赖性减少液体需求(短期58%±11%,长期62%±6%),防止血流动力学失代偿,死亡率从溶媒组50%降至零,并降低组织湿/干重比。作者认为CCR2是减少液体需求和防止失血性休克复苏期间血流动力学失代偿所致死亡的药物靶点。

要点

  • 失血性休克大鼠模型中,INCB3284(1.1和5.5 μmol/kg)剂量依赖性减少液体需求,短期实验减少58%±11%,复苏至t=300分钟时减少62%±6%。
  • 复苏至t=300分钟时,INCB3284(5 μmol/kg)防止血流动力学失代偿,死亡率从溶媒组的50%降至零,并降低总体组织湿重/干重比。
  • 健康麻醉大鼠中,溶媒组血压持续下降0.09±0.01 mm Hg/min(p<0.001),而注射INCB3284后血压保持恒定。
  • CCR5拮抗剂Maraviroc(5.5 μmol/kg)与溶媒组在液体需求上无法区分,提示效应为CCR2所介导。
  • 失血和液体复苏期间,CCR2激动剂CCL2、CCL5和CCL11的全身浓度升高。

适用人群与场景

  • 雄性Sprague-Dawley大鼠,包括健康麻醉大鼠和失血30分钟后的失血性休克大鼠模型。

处置流程与药物剂量

  • 健康麻醉大鼠:给予递增剂量的INCB3284或溶媒。
  • 失血性休克短期实验:失血30分钟后给予INCB3284(1.1和5.5 μmol/kg)、Maraviroc(对照,5.5 μmol/kg)或溶媒,随后液体复苏维持血压至t=90分钟。
  • 失血性休克长期实验:失血和液体复苏后给予5 μmol/kg INCB3284或溶媒,复苏至t=300分钟。

研究设计与关键结果

  • 研究设计:随机前瞻性治疗研究,大学实验室,雄性Sprague-Dawley大鼠。
  • 离体阻力动脉压力肌动图实验中,INCB3284不影响大鼠阻力动脉的固有功能。
  • 健康麻醉大鼠中,溶媒组血压持续下降0.09±0.01 mm Hg/min(p<0.001),而注射INCB3284后血压保持恒定。
  • 失血和液体复苏期间,CCR2激动剂CCL2、CCL5和CCL11的全身浓度升高。
  • 短期实验中,INCB3284剂量依赖性减少液体需求58%±11%,而Maraviroc和溶媒组无法区分。
  • 复苏至t=300分钟时,INCB3284减少液体需求62%±6%,防止血流动力学失代偿,死亡率从溶媒组的50%降至零,并降低总体组织湿重/干重比。

证据类型、等级与局限

  • 证据类型:随机前瞻性治疗研究,动物实验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,CCR2参与正常心血管功能调节以及失血性休克和液体复苏的心血管应激反应。
  • 作者认为,本研究将CCR2确定为减少液体需求并防止失血性休克复苏期间血流动力学失代偿所致死亡的药物靶点。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: Clinical correlations suggest that systemic chemokine (C-C motif) ligand (CCL) 2 release may contribute to blood pressure regulation and the development of hemodynamic instability during the early inflammatory response to traumatic-hemorrhagic shock. Thus, we investigated whether blockade of the principal CCL2 receptor chemokine (C-C motif) receptor (CCR) 2 affects blood pressure in normal animals, and hemodynamics and resuscitation fluid requirements in hemorrhagic shock models.

DESIGN: Randomized prospective treatment study.

SETTING: University laboratory.

SUBJECTS: Male Sprague-Dawley rats.

INTERVENTIONS: First, treatment of healthy anesthetized rats with increasing doses of INCB3284 or vehicle. Second, rats were hemorrhaged for 30 minutes, followed by treatment with the CCR2 antagonist INCB3284 (1.1 and 5.5 μmol/kg), the CCR5 antagonist Maraviroc (=control, 5.5 μmol/kg) or vehicle, and subsequent fluid resuscitation to maintain blood pressure until t = 90 minutes. Third, treatment of rats with 5 μmol/kg INCB3284 or vehicle after hemorrhage and fluid resuscitation until t = 300 minutes.

MEASUREMENTS AND MAIN RESULTS: INCB3284 did not affect intrinsic function of isolated rat resistance arteries in pressure myography experiments. Blood pressure in anesthetized vehicle-treated animals continuously decreased by 0.09 ± 0.01 mm Hg/min (p < 0.001) but remained constant after INCB3284 injections. Systemic concentrations of the CCR2 agonists CCL2, CCL5, and CCL11 increased during hemorrhage and fluid resuscitation. INCB3284 dose-dependently reduced fluid requirements by 58% ± 11% in short-term experiments, whereas Maraviroc and vehicle-treated animals were indistinguishable. When resuscitation was performed until t = 300 minutes, INCB3284 reduced fluid requirements by 62% ± 6%, prevented from hemodynamic decompensation, reduced mortality from 50% with vehicle treatment to zero, and reduced overall tissue wet-weight/dry-weight ratios.

CONCLUSIONS: Our findings suggest that CCR2 is involved in the regulation of normal cardiovascular function and during the cardiovascular stress response to hemorrhagic shock and fluid resuscitation. The present study identifies CCR2 as a drug target to reduce fluid requirements and to prevent death from hemodynamic decompensation during resuscitation from hemorrhagic shock.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. DeSantis AJ, Weche M, Enten GA, et al. The Chemokine (C-C Motif) Receptor 2 Antagonist INCB3284 Reduces Fluid Requirements and Protects From Hemodynamic Decompensation During Resuscitation From Hemorrhagic Shock. Crit Care Explor. 2022. PMID: 35620770. doi:10.1097/CCE.0000000000000701

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。